BioKDE: Biomedical Knowledge Discovery Engine
Sorted by:  
Results by Year
Article Type
Publication date


Custom range



  399,264 results (0.325 seconds)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
Richard S Finn,  Alexey Aleshin,  Dennis J Slamon.
Breast Cancer Res. 2016 Feb 09; 18(1):17. PMID: 26857361     Free PMC article
Highly Cited. Review.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Oscar M Rueda, Stephen-John Sammut, +21 authors, Christina Curtis.
Nature. 2019 Mar 13; 567(7748):399-404. PMID: 30867590     Free PMC article
Highly Cited.
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Miho Kono, Takeo Fujii, +3 authors, Naoto T Ueno.
JAMA Oncol. 2017 Mar 17; 3(9):1266-1273. PMID: 28301631
Highly Cited. Review.
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Nandini Dey,  Pradip De,  Brian Leyland-Jones.
Pharmacol Ther. 2017 Feb 16; 175:91-106. PMID: 28216025
Highly Cited. Review.
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
Milica Nedeljković,  Ana Damjanović.
Cells. 2019 Aug 22; 8(9):. PMID: 31443516     Free PMC article
Highly Cited. Review.
Treatment of HER2-positive breast cancer: current status and future perspectives.
Carlos L Arteaga, Mark X Sliwkowski, +3 authors, Luca Gianni.
Nat Rev Clin Oncol. 2011 Nov 29; 9(1):16-32. PMID: 22124364
Highly Cited. Review.
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.
Gabrielle Planes-Laine, Philippe Rochigneux, +4 authors, Anthony Gonçalves.
Cancers (Basel). 2019 Jul 22; 11(7):. PMID: 31336685     Free PMC article
Highly Cited. Review.
The role of the insulin-like growth factor-1 system in breast cancer.
Panagiotis F Christopoulos,  Pavlos Msaouel,  Michael Koutsilieris.
Mol Cancer. 2015 Feb 15; 14:43. PMID: 25743390     Free PMC article
Highly Cited. Review.
Gene expression profiling in breast cancer: classification, prognostication, and prediction.
Jorge S Reis-Filho,  Lajos Pusztai.
Lancet. 2011 Nov 22; 378(9805):1812-23. PMID: 22098854
Highly Cited. Review.
MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction.
Farah J Nassar,  Rihab Nasr,  Rabih Talhouk.
Pharmacol Ther. 2016 Dec 01; 172:34-49. PMID: 27916656
Highly Cited. Review.
Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment.
Katja Pinker, Joanne Chin, +2 authors, Linda Moy.
Radiology. 2018 May 22; 287(3):732-747. PMID: 29782246
Highly Cited. Review.
Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
Subarnarekha Chatterji, Emma Krzoska, +5 authors, Valerie Speirs.
Lancet Oncol. 2023 Feb 02; 24(2):e74-e85. PMID: 36725152
Systematic Review. Review.
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.
Felipe Ades, Dimitrios Zardavas, +6 authors, Martine Piccart.
J Clin Oncol. 2014 Jul 21; 32(25):2794-803. PMID: 25049332
Highly Cited. Review.
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
Maria Alice Franzoi, Elisa Agostinetto, +5 authors, Matteo Lambertini.
Lancet Oncol. 2021 Apr 20; 22(7):e303-e313. PMID: 33891888
Review.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Seock-Ah Im, Yen-Shen Lu, +16 authors, Debu Tripathy.
N Engl J Med. 2019 Jun 04; 381(4):307-316. PMID: 31166679
Highly Cited.
The immune system and response to HER2-targeted treatment in breast cancer.
Giampaolo Bianchini,  Luca Gianni.
Lancet Oncol. 2014 Feb 01; 15(2):e58-68. PMID: 24480556
Highly Cited. Review.
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Sherry X Yang,  Eric Polley,  Stanley Lipkowitz.
Cancer Treat Rev. 2016 Mar 09; 45:87-96. PMID: 26995633     Free PMC article
Highly Cited. Review.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Laura M Spring, Seth A Wander, +3 authors, Aditya Bardia.
Lancet. 2020 Mar 09; 395(10226):817-827. PMID: 32145796
Review.
Previous 1 2 3 4 5 6 7 8 9 10 Next